National Institutes of Health

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Integral Molecular, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of innovative technologies to aid drug discovery for diseases such as cancer, HIV, and arthritis. The company offers the Lipoparticle technology, which facilitates the identification and optimization of drug candidates targeting integral membrane proteins. With over 20 years of experience in the field, Integral Molecular has supported more than 400 companies in their research efforts, medication discovery, and vaccine development. Its products play a crucial role throughout the drug discovery process, particularly in the development of antibodies and chemical compounds targeting challenging protein targets.

Advent Therapeutics is a pharmaceutical company based in Lumberville, Pennsylvania, dedicated to developing therapies for micro-orphan applications, specifically targeting serious unmet medical needs in neonatal and pediatric populations. The company focuses on legacy drugs aimed at treating disorders in newborn infants, particularly those in intensive care units. By creating prenatal, neonatal, and pediatric medications, Advent Therapeutics enables healthcare professionals to provide advanced care for vulnerable patients, addressing critical gaps in existing treatment options for this underserved demographic.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

The University of Pittsburgh, established in 1787 as the Pittsburgh Academy, is a prominent state-related research university recognized for its academic excellence and research capabilities. It is a member of the Association of American Universities, which includes 62 leading doctorate-granting institutions in North America. The university ranks 24th globally and is recognized as one of the top public universities in the United States, holding the top position in Pennsylvania. The University of Pittsburgh is noted for its strong research productivity and impact, as evidenced by its high ranking in the Performance Rankings of Scientific Papers for World Universities. The university's Pittsburgh School of Medicine, founded in 1886, provides professional medical education, including a Doctor of Medicine (MD) degree. Pitt's students have received numerous prestigious awards, including four Rhodes Scholarships between 2006 and 2012, making it one of the few public institutions to achieve such recognition.

Actuated Medical, Inc. engages in outsourced research and development, designing and modeling, prototyping, and manufacturing medical devices. It offers occlusion clearing systems, such as NG-Clear for removing and disintegrating nasogastric (NG) tube clogs; and PEG-Clear for clearing and breaking up percutaneous endoscopic gastrostomy (PEG) tube clogs. The company also provides controlled tissue penetration systems, including resonance assisted insertion lancets for humane blood sampling of research subjects; low insertion force epidural systems for the entry of epidural needles; and resonance assisted vascular entry needles for aiding in vascular access for compromised and difficult access patients. In addition, Actuated Medical, Inc. offers magnetic resonance imaging compatible systems, such as direct drive motor for improving patient care by enabling various diagnostic and surgical procedures to be performed during MRI imaging; and transdermal patches for administering long-term and controlled-delivery medications subcutaneously. The company was formerly known as Piezo Resonance Innovations, Inc. and changed its name to Actuated Medical, Inc. in September 2011. Actuated Medical, Inc. was founded in 2006 and is based in Bellefonte, Pennsylvania.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

CytoAgents, Inc. is a biotechnology company based in Pittsburgh, Pennsylvania, established in 2018. The company specializes in developing protein-based drugs aimed at treating viral infections, particularly influenza, and addressing life-threatening symptoms associated with Cytokine Release Syndrome (CRS). CRS is an overreaction of the immune system that results in systemic inflammation, often referred to as a cytokine storm. One of its primary products, GP1681, acts as an agonist of a G-protein coupled receptor, targeting the immune response in various medical conditions. CytoAgents focuses on creating treatments for multiple indications with significant unmet medical needs, including those arising from oncology CAR-T cell therapy, COVID-19, and respiratory epidemics, thereby providing healthcare professionals with innovative tools to manage patients experiencing severe immune reactions.

Pennsylvania State University, established in 1855, is a comprehensive public research university with a mission to provide accessible, high-quality education and to support the people of Pennsylvania through teaching, research, and service. It offers over 140 undergraduate and 180 graduate programs across its 24 campuses, with a strong focus on liberal arts, sciences, and professional fields. The university is renowned for its medical school, the Perelman School of Medicine, and its veterinary school, Penn Vet, both of which are leaders in medical research and education. Penn State also houses the Smeal College of Business, a top-ranked business school. The university's commitment to community engagement is evident through its numerous volunteer and community service programs. It manages its endowment fund through the Penn State Investment Council, with the Office of Investment Management overseeing the long-term investment pool.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior develops a platform that combines wearable devices and machine learning algorithms to monitor key physiological signals such as heart rate and motion. This system, known as Recovery, is designed to support mental health recovery and wellness by delivering timely interventions based on real-time data. By utilizing a software-as-a-service (SaaS) model, Behaivior empowers individuals to maintain their recovery process while enabling care providers to better assist their clients. The integration of AI and behavioral health technology allows Behaivior to recognize patterns in human behavior, ultimately aiming to enhance mental well-being and reduce the incidence of crises, including relapse.

Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for acute pulmonary and cardiovascular diseases. The company's lead development programs include istaroxime, currently in Phase 2b clinical trials for treating acute decompensated heart failure and early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials for respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for lung injury from COVID-19; and rostafuroxin, in Phase 2b trials for genetically associated hypertension. Windtree's proprietary technology platform features a synthetic, peptide-containing surfactant (KL4 surfactant) similar to natural pulmonary surfactant, along with novel drug-delivery technologies for noninvasive administration. The company was formerly known as Discovery Laboratories and is headquartered in Warrington, Pennsylvania.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for acute pulmonary and cardiovascular diseases. The company's lead development programs include istaroxime, currently in Phase 2b clinical trials for treating acute decompensated heart failure and early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials for respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for lung injury from COVID-19; and rostafuroxin, in Phase 2b trials for genetically associated hypertension. Windtree's proprietary technology platform features a synthetic, peptide-containing surfactant (KL4 surfactant) similar to natural pulmonary surfactant, along with novel drug-delivery technologies for noninvasive administration. The company was formerly known as Discovery Laboratories and is headquartered in Warrington, Pennsylvania.

Windtree Therapeutics is a biotechnology company focused on developing innovative therapies for acute pulmonary and cardiovascular diseases. The company's lead development programs include istaroxime, currently in Phase 2b clinical trials for treating acute decompensated heart failure and early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase 2b trials for respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for lung injury from COVID-19; and rostafuroxin, in Phase 2b trials for genetically associated hypertension. Windtree's proprietary technology platform features a synthetic, peptide-containing surfactant (KL4 surfactant) similar to natural pulmonary surfactant, along with novel drug-delivery technologies for noninvasive administration. The company was formerly known as Discovery Laboratories and is headquartered in Warrington, Pennsylvania.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Venatorx Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery and development of novel anti-infective agents aimed at treating multi-drug-resistant bacterial infections and challenging viral infections. Founded in 2010 and based in Malvern, Pennsylvania, the company specializes in developing antibacterial drugs to combat resistant infections commonly encountered in hospital and community settings, such as those caused by MRSA, Pseudomonas spp., and Salmonella spp. Venatorx employs innovative chemical approaches to create treatments that exhibit selective and potent activity against various resistant bacterial strains, thereby providing healthcare professionals with broader treatment options to address significant unmet medical needs.

Trevena, Inc. is a biopharmaceutical company based in Chesterbrook, Pennsylvania, established in 2007. The company is dedicated to the development and commercialization of innovative medicines aimed at treating central nervous system disorders. Its product candidates include Oliceridine injection, which is designed for managing moderate-to-severe acute pain and has completed Phase III clinical trials, and TRV250, a delta-opioid receptor agonist that has finished Phase I trials for acute migraine treatment. Other candidates in development include TRV734, targeting both acute and chronic pain, and TRV027, which is being evaluated for acute heart failure. Additionally, Trevena is collaborating with Imperial College London to study TRV027 in the context of COVID-19. The company employs a specialized approach using G protein biased ligands to enhance the efficacy and safety of its therapeutics, addressing the limitations of existing GPCR-targeted drugs.